

Barry Burgdorf

Partner

Houston

Biography

Barry Burgdorf helps public and private companies, emerging companies, and venture capital, private equity, universities, and higher education clients, with a variety of complex mergers, acquisitions, financings, IP, and other corporate transactions in the life sciences and education sectors, with particular focus on technology, software, IT, AI, commercialization, research, and development.

He has served as general counsel, outside counsel, and as part of the corporate suite at a life sciences company offering AI powered diagnostic tools for radiologists and at a biotech venture capital fund, providing him with a holistic view and an inside track on business-critical needs. Barry also regularly advises clients in the higher education space, representing both universities and corporations.

Following his time as a business litigator, Barry was a corporate securities and M&A partner at another global law firm. Barry also previously served as Vice Chancellor and General Counsel of the University of Texas System, where, for over eight years, he served as a key member of the leadership team and oversaw legal, real estate, cybersecurity, IT, and technology transfer matters. As Vice Chancellor and GC of UT System, Barry negotiated with several U.S. government agencies, including The Department of Education, The Department of Energy, The Department of Homeland Security, and The National Institutes of Health, among others. He was also the first General Counsel of



Phone

+1 713 632 1415

Fax

+1 713 632 1401

Email

barry.burgdorf@hoganlovells.com

Practices

Government Contracts
IP and Technology Transactions
Joint Ventures
Mergers and Acquisitions
Private Equity
Public Procurement

Industries

Aerospace and Defense
Consumer
Education
Life Sciences and Health Care
Private Capital
Technology and Telecoms

Samsung Austin Semiconductor, where he worked on construction of Samsung's DRAM fabrication plant and several large equity and equipment financings. He is on the Board of several life sciences and health care companies including an AI driven mobile app for advanced pathogen surveillance.

Representative experience

Lead lawyer for numerous life sciences and technology VC financings.

Part of team for going-public reverse-merger.*

Lead transactional counsel for US\$75m venture fund targeted at clinical stage oncology companies.

Lead counsel for US\$100m+ life sciences venture fund.

Represents numerous private life science companies and university spin-outs as corporate counsel and in complex licensing transactions and finance, M&A and other exits.

Represents several life sciences companies commercializing embedded digital health tools and AI-based diagnostic platforms.

Represents several major universities and colleges on technology transfer sponsored research agreements, commercialization, crisis management, gift and donor matters and public-private partnerships.

Represents faculty members on research and technology commercialization matters and technology startups.

Successfully opposed the federal government's plan to construct a border fence on the UT Brownsville campus.*

Advised on the implementation of a US\$34m multifaceted IT security improvement program.*

Led the successful response to a comprehensive multiyear IRS audit of significant operational and tax issues with a result of no taxes due or negative findings.*

Areas of focus

Corporate and Commercial Transactions

Digital Health

Emerging Companies

Medical Devices

Pharmaceuticals and Biotechnology

Student Financial Aid

Technology Contracts

Technology Transfer, Deemed Exports, and University Based Fundamental Research

Education and admissions

Education

J.D., The University of Texas School of Law, with honors, 1990

M.B.A., Southern Methodist University, 1986

B.B.A., The University of Texas at Austin, 1985

Bar admissions and qualifications

Texas

Advised on numerous technology transfer, licensing, and startup transactions, and on the creation and establishment of US\$50m Horizon Fund.*

*Matter handled prior to joining Hogan Lovells.

Latest thinking and events

- News
 - World Stem Cell Summit offers guidance on positioning your regenerative medicine start-up for success
- Sponsorships and Speaking Engagements
 - 2022 World Stem Cell Summit
- Press Releases
 - Life Sciences Duo Bolsters Hogan Lovells' Houston Corporate Team